MLAB Stock Analysis: Mesa Laboratories | NASDAQ

Sterilization Indicators, Genetic Analysis, Protein Analysis, Calibration Instruments

Total Rating 51

Safety 65

Buy Signal 0.28

Scientific & Technical Instruments
Industry Rotation: -2.1

Market Cap: 731M
Avg Turnover: 18.9M

Risk 3d forecast

Volatility54.5%

VaR 5^th Pctl9.06%

VaR vs Median0.86%

Reward TTM

Sharpe Ratio1.44

Rel. Str. IBD92.2

Rel. Str. Peer Group73.2

Character TTM

Beta1.123

Beta Downside1.048

Hurst Exponent0.364

Drawdowns 3y

Max DD62.78%

CAGR/Max DD0.01

CAGR/Mean DD0.03

EPS (Earnings per Share)

EPS CAGR: 5.36%
EPS Trend: 21.2%

Last SUE: -0.70
Qual. Beats: 0

Revenue

Rev. CAGR: 6.84%
Rev. Trend: 96.6%

Last SUE: -0.39
Qual. Beats: 0

Warnings

P/E Ratio 146.8

Altman Z'' In Financial Distress Zone

Choppy

Tailwinds

Rs Leader

Seasonality 11.6 years of data

Jan +2.7% 18

Feb -5.4% 6

Mar -0.5% 8

Apr +1.1% 2

May -3.1% 21

Jun -1.9% 21

Jul +2.1% 32

Aug -4.4% 37

Sep +1.4% 14

Oct -0.8% 16

Nov +0.4% 13

Dec +2.1% 31

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: MLAB Mesa Laboratories

Mesa Laboratories, Inc. (NASDAQ: MLAB) is a Lakewood, Colorado-based company that develops, manufactures, and services life sciences tools and quality control products across four operating segments: Sterilization and Disinfection Control (biological and chemical indicators for pharma, medical device, and healthcare settings), Clinical Genomics (the MassARRAY genetic analysis platform and related consumables), Biopharmaceutical Development (Gyrolab immunoassay systems and PurePep peptide synthesis instruments), and Calibration Solutions (quality control instruments sold under the DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands). Founded in 1982 and public since 1995, Mesa sells globally with operations in North America, Europe, and Asia Pacific.

The business model follows a typical life sciences tools structure, combining capital equipment (such as MassARRAY systems, Gyrolab xPand/xPlore, and PurePep Chorus/Synthesis instruments) with recurring consumables revenue from reagent kits, microfluidic disks, chemical indicators, and calibration consumables. As a small-cap Health Care company in the GICS Life Sciences Tools & Services sub-industry, Mesa serves regulated end markets-including pharmaceutical manufacturing, clinical laboratories, hospitals, and medical device production-where validation and quality control are mandatory, which tends to support demand stability for its indicator and calibration products.

Headlines to Watch Out For

Sterilization Disinfection Control segment drives revenue from pharma healthcare demand
Biopharmaceutical Development growth depends on Gyrolab and peptide synthesis adoption
Clinical Genomics MassARRAY faces competition from next-generation sequencing platforms

Piotroski VR-10 (Strict) 5.5

Net Income: 4.80m TTM > 0 and > 6% of Revenue
FCF/TA: 0.13 > 0.02 and ΔFCF/TA 5.66 > 1.0
NWC/Revenue: 21.30% < 20% (prev -21.14%; Δ 42.45% < -1%)
CFO/TA 0.13 > 3% & CFO 55.7m > Net Income 4.80m
Net Debt (127.1m) to EBITDA (40.6m): 3.13 < 3
Current Ratio: 2.07 > 1.5 & < 3
Outstanding Shares: last quarter (5.76m) vs 12m ago 3.67% < -2%
Gross Margin: 65.99% > 18% (prev 60.29%; Δ 5.70% > 0.5%)
Asset Turnover: 58.42% > 50% (prev 55.62%; Δ 2.80% > 0%)
Interest Coverage Ratio: 1.62 > 6 (EBIT TTM 17.6m / Interest Expense TTM 10.9m)

Altman Z'' 0.54

A: 0.13 (Total Current Assets 102.8m - Total Current Liabilities 49.6m) / Total Assets 419.2m
B: -0.44 (Retained Earnings -183.8m / Total Assets 419.2m)
C: 0.04 (EBIT TTM 17.6m / Avg Total Assets 427.5m)
D: 0.82 (Book Value of Equity 188.8m / Total Liabilities 230.5m)
Altman-Z'' = 0.54 = B

Beneish M -3.23

DSRI: 0.85 (Receivables 34.4m/39.1m, Revenue 249.7m/242.4m)
GMI: 0.91 (GM 60.29% / 65.99%)
AQI: 0.97 (AQ_t 0.68 / AQ_t-1 0.70)
SGI: 1.03 (Revenue 249.7m / 242.4m)
TATA: -0.12 (NI 4.80m - CFO 55.7m) / TA 419.2m)
Beneish M = -3.23 (Cap -4..+1) = AA

What is the price of MLAB shares?

As of September 07, 2026, the stock is trading at USD 127.78 with a total of 100,553 shares traded. Over the past week, the price has changed by -0.89%, over one month by +26.50%, over three months by +17.24% and over the past year by +99.92%.

Current recommended Stop Loss: 121.00 (which is 5.3% or 1.3 ATR below the current price).

Is MLAB a buy, sell or hold?

Mesa Laboratories has received a consensus analysts rating of 3.50. Therefore, it is recommended to hold MLAB.

StrongBuy: 2
Buy: 0
Hold: 1
Sell: 0
StrongSell: 1

What are the forecasts/targets for the MLAB price?

Analysts Target Price	117.5	-8%

Mesa Laboratories (MLAB) - Fundamental Data Overview as of 04 September 2026

Market Cap USD = 731.1m (731.1m USD * 1.0 USD.USD)
P/E Trailing = 146.7977
P/E Forward = 35.2113
P/S = 2.9276
P/B = 3.7196
Revenue TTM = 249.7m USD
EBIT TTM = 17.6m USD
EBITDA TTM = 40.6m USD
Long Term Debt = 145.9m USD (from longTermDebt, last fiscal year)
Short Term Debt = 8.26m USD (from shortTermDebt, last quarter)
Debt = 157.8m USD (corrected: LT Debt 145.9m + ST Debt 8.26m) + Leases 3.69m
Net Debt = 127.1m USD (calculated: Debt 157.8m - CCE 30.7m)
Enterprise Value = 858.2m USD (731.1m + Debt 157.8m - CCE 30.7m)
Interest Coverage Ratio = 1.62 (Ebit TTM 17.6m / Interest Expense TTM 10.9m)
EV/FCF = 15.29x (Enterprise Value 858.2m / FCF TTM 56.1m)
FCF Yield = 6.54% (FCF TTM 56.1m / Enterprise Value 858.2m)
FCF Margin = 22.47% (FCF TTM 56.1m / Revenue TTM 249.7m)
Net Margin = 1.92% (Net Income TTM 4.80m / Revenue TTM 249.7m)
Gross Margin = 65.99% ((Revenue TTM 249.7m - Cost of Revenue TTM 84.9m) / Revenue TTM)
Gross Margin QoQ = 64.87% (prev 73.21%)
Tobins Q-Ratio = 2.05 (Enterprise Value 858.2m / Total Assets 419.2m)
Interest Expense / Debt = 6.88% (Interest Expense 10.9m / Debt 157.8m)
Taxrate = 48.69% (4.55m / 9.36m)
NOPAT = 9.04m (EBIT 17.6m * (1 - 48.69%))
Current Ratio = 2.07 (Total Current Assets 102.8m / Total Current Liabilities 49.6m)
Debt / Equity = 0.84 (Debt 157.8m / totalStockholderEquity, last quarter 188.8m)
Debt / EBITDA = 3.13 (Net Debt 127.1m / EBITDA 40.6m)
Debt / FCF = 2.26 (Net Debt 127.1m / FCF TTM 56.1m)
Total Stockholder Equity = 185.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.12% (Net Income 4.80m / Total Assets 419.2m)
RoE = 2.59% (Net Income TTM 4.80m / Total Stockholder Equity 185.0m)
RoCE = 5.32% (EBIT 17.6m / Capital Employed (Equity 185.0m + L.T.Debt 145.9m))
RoIC = 2.47% (NOPAT 9.04m / Invested Capital 365.3m)
WACC = 8.79% (E(731.1m)/V(888.9m) * Re(9.93%) + D(157.8m)/V(888.9m) * Rd(6.88%) * (1-Tc(0.49)))
Discount Rate = 9.93% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.02 | Cagr: 2.94%
[DCF] Terminal Value 76.54% ; FCFF base≈47.1m ; Y1≈54.0m ; Y5≈79.5m
[DCF] Fair Price = 175.7 (EV 1.11b - Net Debt 127.1m = Equity 983.0m / Shares 5.60m; r=8.79% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 21.20 | EPS CAGR: 5.36% | SUE: -0.70 | # QB: 0
Revenue Correlation: 96.59 | Revenue CAGR: 6.84% | SUE: -0.39 | # QB: 0
EPS current Quarter (2026-09-30): EPS=2.24 | Chg30d=-17.95% | Revisions=+25% | Analysts=1
EPS next Quarter (2026-12-31): EPS=2.71 | Chg30d=-18.62% | Revisions=+25% | Analysts=1
EPS current Year (2027-03-31): EPS=9.95 | Chg30d=-14.37% | Revisions=+25% | GrowthEPS=+19.2% | GrowthRev=+2.5%
EPS next Year (2028-03-31): EPS=10.27 | Chg30d=-16.30% | Revisions=+0% | GrowthEPS=+3.2% | GrowthRev=+5.9%